S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
NASDAQ:TTNP

Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis

$7.26
0.00 (0.00%)
(As of 04/16/2024 ET)
Today's Range
$7.26
$7.26
50-Day Range
$6.27
$9.41
52-Week Range
$5.00
$16.60
Volume
291 shs
Average Volume
12,470 shs
Market Capitalization
$6.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TTNP stock logo

About Titan Pharmaceuticals Stock (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

TTNP Stock Price History

TTNP Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Titan Pharmaceuticals Inc (TTNP)
Titan Pharmaceuticals, Inc. (TN70.F)
Titan Pharmaceuticals Inc TTNP
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
TTNP - Titan Pharmaceuticals, Inc.
TTNP Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals Provides Shareholder Update
See More Headlines
Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/30/2021
Today
4/16/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TTNP
Employees
4
Year Founded
1992

Profitability

Net Income
$-5,570,000.00
Net Margins
-2,014.71%
Pretax Margin
-3,026.63%

Debt

Sales & Book Value

Annual Sales
$180,000.00
Book Value
$8.82 per share

Miscellaneous

Free Float
686,000
Market Cap
$6.60 million
Optionable
Optionable
Beta
1.33

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. David Elliot Lazar (Age 33)
    CEO & Principal Financial Officer
    Comp: $726.08k
  • Dr. Katherine L. Beebe-DeVarney Ph.D. (Age 63)
    President, COO & Director
    Comp: $308k
  • Mr. Mike Fritz
    National Sales Director
  • Jennifer Kiernan
    Executive Assistant to CEO & Investor Communications Coordinator
  • Joe Schrei
    Executive Director of Commercial Operations

TTNP Stock Analysis - Frequently Asked Questions

How have TTNP shares performed in 2024?

Titan Pharmaceuticals' stock was trading at $8.25 at the beginning of the year. Since then, TTNP stock has decreased by 12.0% and is now trading at $7.2572.
View the best growth stocks for 2024 here
.

Are investors shorting Titan Pharmaceuticals?

Titan Pharmaceuticals saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 3,900 shares, a decline of 67.5% from the March 15th total of 12,000 shares. Based on an average daily trading volume, of 12,500 shares, the short-interest ratio is currently 0.3 days. Approximately 0.6% of the shares of the company are sold short.
View Titan Pharmaceuticals' Short Interest
.

When is Titan Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our TTNP earnings forecast
.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) posted its quarterly earnings data on Tuesday, March, 30th. The specialty pharmaceutical company reported ($17.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($26.60) by $9.40. Titan Pharmaceuticals had a negative trailing twelve-month return on equity of 165.90% and a negative net margin of 2,014.71%.

When did Titan Pharmaceuticals' stock split?

Titan Pharmaceuticals shares reverse split on Tuesday, January 9th 2024. The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Titan Pharmaceuticals own?
How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TTNP) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners